RecruitingPhase 2NCT05891821

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Sponsor

Immune Oncology Research Institute

Enrollment

20 participants

Start Date

Sep 1, 2023

Study Type

INTERVENTIONAL

Conditions

Lymphoma

Summary

The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas. Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests balstilimab, an immunotherapy drug, for people with Hodgkin lymphoma or primary mediastinal B-cell lymphoma that has returned or stopped responding to all standard treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma confirmed by biopsy - You have relapsed or your cancer no longer responds to treatment, and there are no other standard options available **You may NOT be eligible if...** - You still have standard treatment options available - You have a different type of lymphoma - You cannot give written consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.